Navigation Links
Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
Date:9/30/2013

mpound safe for long-term, chronic use.

About Psoriasis

Psoriasis is a chronic autoimmune skin disease that occurs when the immune system mistakenly speeds up the growth cycle of skin cells. It affects up to 7.5 million Americans and can be difficult to treat because of side effects such as atrophy, or thinning of the skin, with long-term use.

Plaque psoriasis is the most common form of the disease in which people develop itchy skin spots, red patches, and a silvery white buildup of dead skin cells most often appearing on the scalp, lower back, knees, and elbows.

According to a patient survey conducted in the U.S. between 2001 and 2008 by the National Psoriasis Foundation, 33% of patients with mild disease and 60% of patients with moderate-to-severe psoriasis reported that their disease significantly affects their everyday life.

About Moleculin

Moleculin is a clinical-stage pharmaceutical company advancing a new therapeutic approach to inflammatory and proliferative skin diseases, including psoriasis, atopic dermatitis, actinic keratosis, and several skin cancers. The Company's topical compounds are based on the direct inhibition of activated STAT3 (p-STAT3), an important target in the fight against chronic skin diseases. MOL4249, the Company's lead product candidate, is currently being studied in psoriasis. Early clinical studies with this p-STAT3 inhibitor suggest improved efficacy and tolerability for the treatment of mild-to-moderate psoriasis. For more information, visit moleculin.com.


'/>"/>
SOURCE Moleculin, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Allied Healthcare Products Reports Loss On Sales Decline
3. TPI Reports Fiscal Year 2013 Financial Results
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
7. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
8. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
9. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. Omeros Reports Additional Positive Results from OMS824 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 2 Data presented today,at the Annual Congress ... investigational oral Factor Xa inhibitor DU-176b reduced the ... patients,undergoing elective unilateral hip replacement surgery. There was ... and the,observed bleeding rates were low across the ...
... Stenting Safe and Effective in Patients ... Has Been Open-Heart Surgery, WASHINGTON, Sept. 1 ... patients with very complex coronary,artery disease can safely choose ... open-heart surgery, says The Society for,Cardiovascular Angiography and Interventions ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... especially common after the death of a spouse , , ... keep up active social lives as they age may ... finds. , Being socially active may increase feelings ... helping maintain memory, researchers say. Social interaction may also ...
... May 29 PartnerRe Ltd.,(NYSE: PRE ) today ... Benchimol is scheduled to present at the Fox,Pitt-Kelton Cochran ... Opportunities for the Insurers... and the Contrast with,Banks." The ... 6, 2008 from 9 a.m. - 2 p.m. local ...
... published a,new report designed to provide critical strategic ... in the market for diagnostics and treatments,in this ... &,Analysis: Alzheimer,s Disease," is based on in-depth interviews ... involved in ongoing,research., "There is some real ...
... New three-year agreement extends alliance members, access to medical product ... ... systems., LOUDON, Tenn., May 29 Adroit ... by Premier,Purchasing Partners, LP. The new agreement centers on Adroit,s leading,Soft-Temp(R) ...
... Help Firms That Already Offer Insurance to Workers, ERIE, ... than 10,000 uninsured adults in Erie County -- many of ... are on a waiting list,to receive health care coverage -- ... them gain access to health insurance., He said small ...
... DR ),is excited to announce the creation ... division and the errors and omissions (E&O),division., ... leadership of senior vice president and national practice,leader, ... combines all,of Darwin,s health care-related professional liability teams ...
Cached Medicine News:Health News:Active Social Life Helps Keep Aging Mind Sharp 2Health News:Active Social Life Helps Keep Aging Mind Sharp 3Health News:PartnerRe Executive Vice President & Chief Financial Officer Albert Benchimol to Present at the FPK CCW Credit Risk Conference in London on June 6, 2008 2Health News:Cardiovascular Meds May Be Beneficial in Alzheimer's Disease, According to MedPredict Report 2Health News:Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 3Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 4Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 2Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 3
... Stealthstation Siremobil Iso-C3D C-Arm imaging system interface ... of mobile C-arm imaging. Combining mobility ... software, the cooperative technologies deliver the most ... 3D imaging is the new standard in ...
... The best of digital mobile imaging ... of,anatomical localization software and instrumentation. Now ... capability to:, Easily Add Visualization ... Dose, Accelerate Intraoperative Decision Making, ...
... the most advanced imaging capabilities into the ... it offers many of the same technologies ... value-oriented platform. Asteion provides the subsecond speed ... scanning, while also supporting everyday, high-resolution scanning ...
... the T.L.I.F. SG Instruments are the ... surgery, offering comprehensive and functionally sound instruments.. ... variety of disc removal and disc preparation ... TLIF procedure. Excellent design, a wide range ...
Medicine Products: